Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
AnaptysBio, Inc. (ANAB)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$45.58-4.06%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
2.42 → 6.75 EPS · FY ending Dec 31, 2027 · 3 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 3 to 3; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for ANAB yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Achieve $390M in Jemperli royalties by 2029 | AnaptysBio aims to reach $390 million in Jemperli royalties by 2029. | Intact | Jemperli royalties fail to grow toward $390 million by 2029 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 1 of 1 supplied quarters. Management reported: “The increase is primarily due to Jemperli royalties increasing 25% and 34% for the three and six months ended June 30, 2026, offset by $9.7 million in revenue recognized for the Vanda license agreement for the three month and six months ended June 30, 2025.” ““ Jemperli continues to demonstrate robust year-over-year growth with major catalysts within the next 6 months including further sales acceleration ex-US, anticipated FDA approval of Jemperli in monotherapy in dMMR/MSI-H neoadjuvant rectal cancer, as well as a judgement expected in our litigation with GSK and Tesaro,” said Daniel Faga, president and chief executive officer.” |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
ANAB is a royalty-growth story with a streamlined operating structure, rather than a broad-based, established compounder. Its multi-year view is intact, while management execution is volatile and earnings quality remains fragile.
The valuation evidence is mixed: one measure says ANAB is cheap versus peers, while another shows a 19% premium, and confidence in the valuation model is low. The expectations gap is negative, and the evidence characterizes current pricing as justified because weak execution quality is not paired with the full combination of expensive valuation and turbulence.
Near-term results have been strong, including a reported earnings beat, and Jemperli collaboration revenue rose from $25.6 million in Q1 to $27.5 million in Q2 2026. Management continues to pursue more than $390 million in annualized Jemperli royalties by 2029, but delivery is mixed; erratic earnings surprises make the next report a key risk. The completed First Tracks spin-off and leadership appointments mark structural changes, though the evidence describes operational performance as mixed.
The multi-year thesis depends on continued growth in Jemperli royalties and progress toward management’s 2029 goal. Near term, a guidance cut would be a meaningful negative, while weakening jobs data could weigh on cyclical healthcare names; continued strong results and guidance from sector bellwethers could support sector momentum.
Over the next 1 to 3 years, ANAB’s case rests on royalty growth and consistent execution, against a backdrop of fragile earnings quality and elevated risk. Recent performance supports an intact thesis, but the next guidance update and progress toward the royalty goal matter. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stable and effective management team | A supporting condition in AnaptysBio, Inc.'s published investment case. The stated target is No major executive departures and steady progress on priorities. | Intact | Significant management turnover or failure to execute key initiatives | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Reach at least $390 million revenue in 2026 | AnaptysBio aims to reach $390 million in Jemperli royalties by 2029. | Intact | Revenue falls below $390 million in FY26 | Revenue: $27.488M FY2026-Q2; GAAP. Published target: >= $390 million. Annual target cannot be compared with a quarterly or TTM observation. Sep 21, 202627,488,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 1 of 1 supplied quarters. Management reported: “The increase is primarily due to Jemperli royalties increasing 25% and 34% for the three and six months ended June 30, 2026, offset by $9.7 million in revenue recognized for the Vanda license agreement for the three month and six months ended June 30, 2025.” ““ Jemperli continues to demonstrate robust year-over-year growth with major catalysts within the next 6 months including further sales acceleration ex-US, anticipated FDA approval of Jemperli in monotherapy in dMMR/MSI-H neoadjuvant rectal cancer, as well as a judgement expected in our litigation with GSK and Tesaro,” said Daniel Faga, president and chief executive officer.” Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$5.24 → $6.75 · observed estimates
$0.15B → $0.24B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $5.24 | $153,193,990 | 5 / 7 |
| 2026-07-25 | $5.24 | $153,193,990 | 5 / 7 |
| 2026-07-26 | $5.24 | $153,193,990 | 5 / 7 |
| 2026-07-27 | $5.24 | $153,193,990 | 5 / 7 |
| 2026-07-28 | $5.24 | $153,193,990 | 5 / 7 |
| 2026-07-29 | $5.24 | $153,193,990 | 5 / 7 |
| 2026-07-30 | $5.24 | $153,193,990 | 5 / 7 |
| 2026-07-31 | $5.24 | $153,193,990 | 5 / 7 |
| 2026-08-01 | $5.24 | $153,193,990 | 5 / 7 |
| 2026-08-02 | $5.24 | $153,193,990 | 5 / 7 |
| 2026-08-03 | $5.24 | $153,193,990 | 5 / 7 |
| 2026-08-04 | $5.24 | $153,193,990 | 5 / 7 |
| 2026-08-05 | $5.24 | $153,193,990 | 5 / 7 |
| 2026-08-06 | $5.24 | $153,193,990 | 5 / 7 |
| 2026-08-07 | $1.96 | $153,194,993 | 5 / 5 |
| 2026-08-08 | $5.24 | $153,193,990 | 5 / 7 |
| 2026-08-09 | $5.24 | $153,193,990 | 5 / 7 |
| 2026-08-10 | $5.24 | $153,193,990 | 5 / 7 |
| 2026-08-11 | $5.24 | $153,193,990 | 5 / 7 |
| 2026-08-12 | $5.24 | $153,193,990 | 5 / 7 |
| 2026-08-13 | $5.24 | $153,193,990 | 5 / 7 |
| 2026-08-14 | $1.96 | $153,194,993 | 5 / 5 |
| 2026-08-15 | $1.96 | $153,194,993 | 5 / 5 |
| 2026-08-16 | $1.96 | $153,194,993 | 5 / 5 |
| 2026-08-17 | $1.96 | $153,194,993 | 5 / 5 |
| 2026-08-18 | $1.96 | $153,194,993 | 5 / 5 |
| 2026-08-19 | $1.96 | $153,194,993 | 5 / 5 |
| 2026-08-20 | $1.96 | $153,194,993 | 5 / 5 |
| 2026-08-21 | $1.96 | $153,194,993 | 5 / 5 |
| 2026-08-22 | $1.96 | $153,194,993 | 5 / 5 |
| 2026-08-23 | $1.96 | $137,780,464 | 5 / 5 |
| 2026-08-24 | $1.96 | $137,780,464 | 5 / 5 |
| 2026-08-25 | $1.41 | $131,351,344 | 5 / 5 |
| 2026-08-26 | $1.41 | $131,351,344 | 5 / 5 |
| 2026-08-27 | $1.41 | $131,351,344 | 5 / 5 |
| 2026-08-28 | $1.41 | $131,351,344 | 5 / 5 |
| 2026-08-29 | $1.41 | $131,351,344 | 5 / 5 |
| 2026-08-30 | $1.41 | $103,810,850 | 5 / 5 |
| 2026-08-31 | $1.41 | $103,810,850 | 5 / 5 |
| 2026-09-01 | $1.41 | $103,920,500 | 5 / 5 |
| 2026-09-02 | $1.41 | $103,920,500 | 5 / 5 |
| 2026-09-03 | $1.41 | $103,920,500 | 5 / 5 |
| 2026-09-04 | $2.86 | $136,160,667 | 5 / 5 |
| 2026-09-05 | $2.86 | $136,160,667 | 4 / 5 |
| 2026-09-06 | $2.86 | $136,160,667 | 4 / 5 |
| 2026-09-07 | $2.86 | $136,160,667 | 4 / 5 |
| 2026-09-08 | $2.86 | $136,160,667 | 4 / 5 |
| 2026-09-09 | $2.86 | $136,160,667 | 4 / 5 |
| 2026-09-10 | $2.86 | $136,160,667 | 4 / 5 |
| 2026-09-11 | $2.86 | $158,486,157 | 4 / 5 |
| 2026-09-12 | $2.86 | $158,486,157 | 4 / 5 |
| 2026-09-13 | $2.86 | $158,486,157 | 4 / 5 |
| 2026-09-14 | $2.86 | $158,486,157 | 4 / 5 |
| 2026-09-15 | $2.86 | $158,486,157 | 4 / 5 |
| 2026-09-16 | $2.86 | $158,486,157 | 4 / 4 |
| 2026-09-17 | $2.86 | $158,486,157 | 4 / 4 |
| 2026-09-18 | $2.86 | $158,486,157 | 4 / 4 |
| 2026-09-19 | $2.86 | $158,486,157 | 4 / 4 |
| 2026-09-20 | $2.86 | $158,486,157 | 4 / 4 |
| 2026-09-21 | $2.86 | $158,486,157 | 4 / 4 |
| 2026-09-22 | $2.86 | $151,557,262 | 4 / 4 |
| 2026-09-23 | $2.42 | $188,014,762 | 4 / 4 |
| 2026-09-24 | $2.42 | $188,014,762 | 4 / 4 |
| 2026-09-25 | $2.42 | $188,014,762 | 3 / 4 |
| 2026-09-26 | $2.42 | $188,014,762 | 3 / 4 |
| 2026-09-27 | $2.42 | $188,014,762 | 3 / 4 |
| 2026-09-28 | $2.42 | $188,014,762 | 3 / 4 |
| 2026-09-29 | $2.42 | $188,014,762 | 3 / 4 |
| 2026-09-30 | $2.42 | $188,014,762 | 3 / 4 |
| 2026-10-01 | $2.42 | $188,014,762 | 3 / 4 |
| 2026-10-02 | $2.42 | $188,014,762 | 3 / 4 |
| 2026-10-03 | $2.42 | $188,014,762 | 3 / 4 |
| 2026-10-04 | $2.42 | $188,014,762 | 3 / 4 |
| 2026-10-05 | $2.42 | $188,014,762 | 3 / 4 |
| 2026-10-06 | $2.42 | $188,014,762 | 3 / 4 |
| 2026-10-07 | $7.11 | $296,817,474 | 3 / 4 |
| 2026-10-08 | $7.11 | $296,817,474 | 3 / 4 |
| 2026-10-09 | $7.11 | $296,817,474 | 3 / 4 |
| 2026-10-10 | $7.11 | $296,817,474 | 3 / 4 |
| 2026-10-11 | $6.75 | $195,539,824 | 3 / 4 |
| 2026-10-12 | $6.75 | $195,539,824 | 3 / 4 |
| 2026-10-13 | $6.75 | $195,539,824 | 3 / 4 |
| 2026-10-14 | $6.75 | $195,539,824 | 3 / 4 |
| 2026-10-15 | $6.75 | $195,539,824 | 3 / 4 |
| 2026-10-16 | $6.75 | $195,539,824 | 3 / 4 |
| 2026-10-17 | $6.75 | $195,539,824 | 3 / 4 |
| 2026-10-18 | $6.75 | $195,539,824 | 3 / 4 |
| 2026-10-19 | $6.75 | $243,294,107 | 3 / 4 |
| 2026-10-20 | $6.75 | $243,294,107 | 3 / 4 |
| 2026-10-21 | $6.75 | $243,294,107 | 3 / 4 |
| 2026-10-22 | $6.75 | $243,294,107 | 3 / 4 |
| 2026-10-23 | $6.75 | $243,294,107 | 3 / 4 |
| 2026-10-24 | $6.75 | $243,294,107 | 3 / 4 |
| 2026-10-25 | $6.75 | $243,294,107 | 3 / 4 |
| 2026-10-26 | $6.75 | $243,294,107 | 3 / 4 |
| 2026-10-27 | $6.75 | $243,294,107 | 3 / 4 |
| 2026-10-28 | $6.75 | $243,294,107 | 3 / 4 |
| 2026-10-29 | $6.75 | $243,294,107 | 3 / 4 |
| 2026-10-30 | $6.75 | $243,294,107 | 3 / 4 |
| 2026-10-31 | $6.75 | $243,294,107 | 3 / 4 |
| 2026-11-01 | $6.75 | $243,294,107 | 3 / 4 |
| 2026-11-02 | $6.75 | $243,294,107 | 3 / 4 |
| 2026-11-03 | $6.75 | $243,294,107 | 3 / 4 |
| 2026-11-04 | $6.75 | $243,294,107 | 3 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 8 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.